The Impact of Fasting on Disease Activity and the Gut Microbiota in Patients with Psoriasis and Psoriatic Arthritis - the RiseFast Pilot Study

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The RiseFast pilot study will investigate the clinical, metabolic and immunological effects of fasting and plant-based diet (PBD) on patients with psoriasis (PsO) and psoriatic arthritis (PsA) on their gut microbiota. The project will combine clinical assessments, cytometric profiling, and gut microbiota analysis to explore the relationship between fasting, a plant-based diet, and psoriatic disease. The study includes a 7-day fasting period followed by 11 weeks of PBD, with the goal of improving disease activity, quality of life, and understanding the role of gut microbiota in these conditions. This approach could lead to low-cost, accessible therapeutic options with minimal side effects.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Active plaque psoriasis (PASI ≥3) or Psoriatic Arthritis fulfilling the Classification Criteria for Psoriatic Arthritis (CASPAR) and not meeting MDA criteria

• on stable baseline psoriatic treatment for 12 weeks before enrollment

• ≥ 18 years old

Locations
Other Locations
Germany
Charité - Universitätsmedizin Berlin, Psoriasis-Forschungs- und BehandlungsCentrum
RECRUITING
Berlin
Contact Information
Primary
Anika Rajput Khokhar, MD
risefast@charite.de
+49 30 450 518 329
Time Frame
Start Date: 2025-04-30
Estimated Completion Date: 2026-06-01
Participants
Target number of participants: 30
Treatments
Other: Fasting and Plant-Based Diet
The participants (n=15 with PsO, n=15 with PsA) will undergo an initial 7-day fasting regime according to Buchinger (max. 350 kcal per day as liquids), followed by a dietary intervention that encompasses a plant-based diet (PBD) and time restricted eating (TRE) for 11 weeks.
Related Therapeutic Areas
Sponsors
Leads: Charite University, Berlin, Germany
Collaborators: Max Delbrück Center for Molecular Medicine (MDC), Berlin

This content was sourced from clinicaltrials.gov